Ergoteles LLC Tricida, Inc. Transaction History

Ergoteles LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$7.31 - $11.85 $86,258 - $139,830	-11,800 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$7.35 - $10.63 $86,730 - $125,434	11,800 New	11,800 $97,000
Q4 2021 Feb 14, 2022	SELL	$4.19 - $9.56 $338,631 - $772,629	-80,819 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$3.56 - $4.64 $9,900 - $12,903	-2,781 Reduced 3.33%	80,819 $375,000
Q2 2021 Aug 12, 2021	BUY	$3.95 - $5.41 $205,400 - $281,320	52,000 Added 164.56%	83,600 $361,000

Q1 2021 May 12, 2021	BUY	$4.52 - $7.8 $93,419 - $161,210	20,668 Added 189.06%	31,600 $167,000
Q4 2020 Feb 11, 2021	BUY	$4.37 - $9.46 $47,772 - $103,416	10,932 New	10,932 $77,000

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Ergoteles LLC, based on Form 13F filings with the SEC.

Stay updated on Ergoteles LLC with notifications on news.